Isolated Elevation in Troponin T After Percutaneous Coronary Intervention Is Associated With Higher Long-Term Mortality  by Prasad, Abhiram et al.
I
A
I
A
R
R
I
a
f
a
p
g
a
p
(
n
o
a
s
r
t
(
C
s
t
a
M
a
Journal of the American College of Cardiology Vol. 48, No. 9, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Psolated Elevation in Troponin T
fter Percutaneous Coronary Intervention
s Associated With Higher Long-Term Mortality
bhiram Prasad, MD, FRCP, FACC,* Mandeep Singh, MD, FACC,* Amir Lerman, MD, FACC,*
yan J. Lennon, MS,† David R. Holmes, JR, MD, FACC,* Charanjit S. Rihal, MD, FACC*
ochester, Minnesota
OBJECTIVES The aim of this study was to evaluate whether, in patients with normal post-procedure
CK-MB, an isolated elevation in cardiac troponin T (cTnT) predicts long-term survival.
BACKGROUND Cardiac troponin T is a sensitive and specific marker of myonecrosis. There is little known
about the incidence and prognostic significance of an isolated elevation of cTnT without a rise
in creatine kinase (CK)-MB following PCI.
METHODS We evaluated the outcomes of 1,949 patients from the Mayo Clinic registry who had normal
pre-procedure cTnT and CK-MB, required nonemergency percutaneous coronary interven-
tion (PCI), and had normal CK-MB after the procedure.
RESULTS An elevation in cTnT (cTnT) was observed in 383 patients (19.6%) (median 0.04 ng/ml,
interquartile range 0.03 to 0.06 ng/ml). The TnT status was associated with adverse clinical
and angiographic characteristics, and multivessel PCI. Over the median follow-up duration
of 26 months, mortality (p  0.001) and the combined rate of death and myocardial
infarction (p 0.004) were significantly higher in cTnT patients. Estimated 3-year survival
for those with and without cTnT elevation was 86.9% and 93.2%, respectively. By
multivariate analysis, an elevation in cTnT after PCI was an independent predictor of
increased long-term mortality. A doubling in the post-PCI cTnT was associated with a
partial hazard ratio of 1.20 (95% confidence interval 1.02 to 1.40; p  0.023).
CONCLUSIONS An isolated minor elevation in cTnT after PCI provides long-term prognostic information
regarding mortality and myocardial infarction. (J Am Coll Cardiol 2006;48:1765–70)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.102© 2006 by the American College of Cardiology Foundation
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fn the era of stents and glycoprotein IIb/IIIa inhibitors, minor
nd often asymptomatic elevation in creatine kinase-MB
raction (CK-MB) occurs in approximately 20% of patients
fter percutaneous coronary intervention (PCI) (1,2). The
reponderance of evidence supports the observation that
reater than 5-fold rise in CK-MB above normal is associ-
ted with in-hospital adverse cardiac events and merits
rolonging the hospitalization after elective procedures
1–4), whereas an elevation of CK-MB that is 1 to 5 times
ormal does not appear to significantly influence in-hospital
utcomes.
See page 1771
The data for a relationship between CK-MB elevation
nd long-term survival is less consistent. Several studies
uggest that any elevation of CK-MB is associated with
educed long-term survival, and that there is direct correla-
ion between the magnitude of myonecrosis and mortality
1,5,6). In contrast, others have reported a threshold of
K-MB 5 to 8 times normal to be predictive of long-term
urvival (2,4,7). The differentiation of a continuous versus a
hreshold relationship between post-procedural myonecrosis
From the *Division of Cardiovascular Diseases, Department of Internal Medicine,
nd the †Section of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester,
innesota.t
Manuscript received January 13, 2006; revised manuscript received April 20, 2006,
ccepted April 23, 2006.nd long-term survival is important to establish, because it
rovides insight into the pathophysiologic mechanisms for
he association (8). A threshold of 5 to 8 times normal would
upport a direct effect of myocardial injury on survival, whereas
continuous relationship would be consistent with the
K-MB elevation being a marker of atherosclerotic burden
nd disease activity. We hypothesized that the relationship is
ontinuous, even at very low levels of myonecrosis. The aim
f this study was to evaluate whether, in patients with
ormal postprocedure CK-MB, an isolated elevation in
ardiac troponin T (cTnT) predicts long-term survival.
ETHODS
ince 1979, all patients undergoing percutaneous revas-
ularization at the Mayo Clinic in Rochester, Minnesota,
re prospectively followed in a registry. The registry
ncludes demographic, clinical, angiographic, and proce-
ural data. Immediate and in-hospital events are re-
orded, and each patient is surveyed by telephone using a
tandardized questionnaire at 6 months, 1 year, and then
nnually after the procedure. All adverse events are con-
rmed by reviewing the medical records of the patients
ollowed at our institution and by contacting the patients’
hysicians and reviewing the hospital records of patients
ollowed elsewhere.
The current study included all consecutive patients from
he database for the period of August 1, 2000, when routine
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Troponin T and PCI November 7, 2006:1765–70easurements of cTnT were initiated for our PCI patients,
hrough October 31, 2003. Inclusion criteria were a normal
reprocedure cTnT (below the 10% coefficient of variation
CV] value) and CK-MB. Patients were excluded if they
uffered myocardial infarction (MI) in the week before PCI
r had a post-procedure elevation in CK-MB. Hospital
harts of each patient were reviewed to verify the data, and
he study was approved by the Institutional Review Board.
here were 5,505 PCIs performed on 4,760 unique pa-
ients. One hundred seventeen patients refused use of their
ecords for research, yielding a sample size of 5,368 PCIs.
f these, 1,997 had elevated baseline cTnT, 52 had elevated
aseline CK-MB, 733 had elevated post-PCI CK-MB, and
57 had missing values for at least 1 of these 3 measures.
ifty-two PCIs were excluded for pre-procedural shock or
ecent myocardial infarction (within 7 days before PCI). Of
he remaining 2,177 qualifying PCIs, the first for each of
he 1,949 patients was included.
Blood samples for cardiac biomarkers were collected before
nd at 8 and 16 h after PCI. The analysis was performed using
highly sensitive and precise third-generation assay (Elecsys;
oche Diagnostics, Indianapolis, Indiana). The upper limit of
ormal for the assay is 0.03 ng/ml. The following defini-
ions were used for the database. Myocardial infarction
uring follow-up was defined by the presence of 2 of 3
riteria: chest pain lasting 20 min or longer, new ST/T-
ave changes or Q waves on the electrocardiogram, and
ncreased cardiac biomarker (CK or CK-MB) levels at least
wice the upper limit of the normal range. The number of
iseased coronary arteries was defined by the number of
ajor coronary arteries with luminal diameter stenosis
70%. Patients with 50% stenosis in the left main
oronary artery were considered to have 2-vessel disease if
here was right dominance and 3-vessel disease if there was
eft dominance. Angiographic success was defined as PCI
ith residual stenosis 50% in at least one treatment site.
omplete revascularization was achieved if there were no
emaining stenoses 70%.
tatistical analysis. Data are presented as the mean values
SD or as a frequency (percentage). Kaplan-Meier methods
ere used to estimate survival curves. Survival was analyzed in
uccessful PCIs, with the discharge date as day 0. Compari-
ons between groups are made using Student t test, Pearson
hi-squared statistic, Mann-Whitney rank sum test, and log
ank test for continuous, nominal, ordinal (i.e., number of
iseased vessels, number of vessels treated, and length of
Abbreviations and Acronyms
CABG  coronary artery bypass graft
CK-MB  creatine kinase-MB
CRP  C-reactive protein
cTnT  cardiac troponin T
MI  myocardial infarction
PCI  percutaneous coronary interventiontay), and survival data, respectively. aCox proportional hazards models were used to estimate
artial hazards ratios. Covariate models for each
ollow-up end point were constructed in the following
anner: simple associations with the end point were
stimated for covariates with sufficient data (10% miss-
ng values); covariates significant at the 0.15 level were
ncorporated into a full covariate model; a backward selec-
ion procedure was used (with 0.05 significance threshold)
o produce the final covariate model. Cardiac troponin (base
logarithmic transformation) was then added to the
ovariate-only model. Ejection fraction was dichotomized at
0%, and the hazard ratio for age is based on a 10-year
ncrement in age. All analyses presented here were per-
ormed using SAS software (SAS Institute, Cary, North
arolina).
ESULTS
aseline characteristics. There were 383 (19.6%) patients
ith elevated cTnT (cTnT) (median 0.04 ng/ml; inter-
uartile range 0.03 to 0.06 ng/ml) and normal CK-MB after
CI among the 1,949 patients enrolled in the study. The
linical characteristics of patients with and without cTnT
levation are summarized in Table 1. Patients with a rise in
TnT had more adverse clinical characteristics; they were older,
ore likely to have moderate to severe angina, a history of
ongestive heart failure (CHF), an ejection fraction 40%,
able 1. Baseline Clinical Characteristics
TnT
<0.03 ng/ml
(n  1,566)
TnT
>0.03 ng/ml
(n  383) p Value
ge, yrs 65.8  11.1 69.7  11.1 0.001
ale gender 1,120 (72%) 264 (69%) 0.32
iabetes 423 (27%) 109 (29%) 0.54
ypertension 1,131 (75%) 280 (77%) 0.66
istory of cholesterol 240 mg/dl 1,307 (88%) 302 (87%) 0.43
urrent smoker 202 (13%) 34 (9%) 0.031
urrent/former smoker 1,003 (65%) 241 (64%) 0.71
anadian Heart Class III/IV 911 (58%) 247 (64%) 0.024
HF on presentation 87 (6%) 39 (10%) 0.001
istory of CHF 151 (11%) 65 (20%) 0.001
V ejection fraction 40% 133 (8%) 50 (13%) 0.006
rior MI 544 (36%) 148 (40%) 0.16
rior PTCA 630 (40%) 147 (38%) 0.51
rior CABG 382 (24%) 96 (25%) 0.79
eripheral vascular disease 147 (10%) 52 (14%) 0.013
VA/TIA 172 (11%) 55 (15%) 0.06
oderate/severe renal disease 28 (2%) 13 (3%) 0.050
ody mass index, kg/m2 30.1  5.7 29.5  5.3 0.048
n-hospital medications
Aspirin, no 1,547 (99%) 378 (99%) 0.88
Beta-blockers 1,234 (79%) 296 (77%) 0.52
Lipid-lowering drugs 1,179 (75%) 271 (71%) 0.07
ACE inhibitors 722 (46%) 197 (51%) 0.07
alues expressed as n (%).
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass
rafting; CHF congestive heart failure; CVA cerebrovascular accident; LV left
entricular; MI  myocardial infarction; PTCA  percutaneous transluminal
oronary angioplasty; TIA  transient ischemic attack; TnT  troponin T.nd peripheral vascular disease and less likely to be current
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November 7, 2006:1765–70 Troponin T and PCImokers. There was no difference in the use of beta-blocker,
ngiotensin-converting enzyme inhibitors, and lipid-
owering therapy between the groups.
ngiographic and procedural characteristics. Table 2
ummarizes the angiographic characteristics. Patients with
able 2. Angiographic Characteristics
TnT
<0.03 ng/ml
(n  1,566)
TnT
>0.03 ng/ml
(n  383) p Value
umber of diseased vessels 0.011
Single 528 (36%) 111 (29%)
Double 577 (40%) 133 (38%)
Three 342 (24%) 108 (31%)
ype C lesion 492 (32%) 163 (44%) 0.001
hrombus present 112 (8%) 41 (12%) 0.020
alcified lesion 469 (33%) 143 (41%) 0.003
ccentric lesion 1,097 (82%) 273 (85%) 0.17
ifurcation lesion 180 (12%) 47 (13%) 0.61
stial lesion 239 (23%) 53 (20%) 0.39
evere angulation 32 (2%) 11 (3%) 0.34
inor branches (any lesion) 548 (38%) 138 (39%) 0.72
ajor branches (any lesion) 281 (19%) 79 (22%) 0.20
alues expressed as n (%).
TnT  troponin T.
Table 3. Procedural Characteristics
Nature procedure
Elective
Urgent
Total vessels treated
1
2
3
Total stents placed
Device used
Balloon only
Stent
Cutting balloon
Atherectomy
GP IIb/IIIa administration
Vessel treated
Left main
Left anterior descending
Circumflex
Right
Vein graft intervention
Successful procedure
Post-procedure TIMI 3 flow in all lesions
Post-procedure TIMI 2 or 3 flow in all lesions
Branch occlusion
Intimal tear
In-lab coronary occlusion—reopened
In-lab coronary occlusion—remained
Coronary occlusion within 24 h
Coronary occlusion after 24 h
Coronary embolization
Maximum balloon length (mm)
Maximum device size (mm)Values expressed as n (%).
GP  glycoprotein; TIMI  Thrombolysis In Myocardial InfaTnT had more extensive disease with multivessel coro-
ary artery disease, type C lesions, and lesions associated
ith thrombus, and calcification. Procedural characteristics
re presented in Table 3. Procedural success (98%) and
ost-procedure TIMI (Thrombolysis In Myocardial Infarc-
ion) grade 3 flow (97%) were equally high in both groups.
here was no difference in the use of glycoprotein IIb/IIIa
nhibitors, stents, and atherectomy devices between the
roups. In concert with more extensive disease and adverse
aseline clinical characteristics, cTnT patients underwent
ore urgent procedures, had more multivessel PCI, and had
ore complicated procedural outcomes with more dissec-
ion and branch vessel occlusion.
utcomes. The length of hospitalization was longer
mong cTnT patients (Table 4). There was 1 in-hospital
eath among cTnT patients and none in those with
ormal cTnT levels. The 1,916 patients with successful PCI
ere followed for a median of 26 months; 92% had at least
year of follow-up. Mortality and the combined rate of
eath and MI were significantly higher in cTnT patients
Figs. 1 and 2). Estimated 1, 2, and 3-year survival rates for
hose with and without cTnT elevation were 97% and
TnT
0.03 ng/ml
 1,566)
TnT
>0.03 ng/ml
(n  383) p Value
0.001
853 (54%) 163 (43%)
713 (46%) 220 (57%)
0.005
,339 (86%) 305 (80%)
212 (14%) 73 (19%)
15 (1%) 5 (1%)
1.3  1.0 1.5  1.1 0.001
118 (8%) 26 (7%) 0.62
,352 (86%) 339 (89%) 0.26
158 (10%) 36 (9%) 0.69
29 (2%) 11 (3%) 0.21
750 (48%) 198 (52%) 0.19
34 (2%) 5 (1%) 0.28
687 (44%) 188 (49%) 0.07
386 (25%) 111 (29%) 0.08
562 (36%) 124 (32%) 0.20
121 (8%) 39 (10%) 0.12
,540 (98%) 376 (98%) 0.82
,420 (97%) 352 (97%) 0.87
,449 (99%) 357 (99%) 0.73
18 (1%) 10 (3%) 0.031
203 (13%) 67 (18%) 0.022
4 (0.3%) 2 (0.5%) 0.40
4 (0.3%) 1 (0.2%) 0.98
6 (0.4%) 2 (0.5%) 0.70
0 0
0 0
6.0  6.8 16.1  5.2 0.79
3.3  0.7 3.4  0.6 0.20<
(n
1
1
1
1
1
1rction; TnT  troponin T.
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Troponin T and PCI November 7, 2006:1765–708.1%, 90.2% and 95.9%, and 86.9% and 93.2%, respec-
ively. By multivariate analysis an elevation in post-PCI
TnT, age, diabetes, peripheral vascular disease, ejection
raction 40%, calcified lesion, and saphenous vein graft
CI were independent predictors of increased long-term
ortality (Table 5). There was no evidence of a nonlinear or
hreshold effect for the association between post-PCI cTnT
nd the time to mortality. A doubling in the post-PCI
TnT measure was associated with a partial hazard ratio of
.20 (95% confidence interval 1.02 to 1.4; p  0.023).
ISCUSSION
he major findings of the present study are that following
CI in patients with normal baseline cTnT: 1) isolated
inor elevation in cTnT, with normal CK-MB, occurs in
bout 20% of patients; 2) the rise in cTnT is independently
ssociated with increased long-term mortality; but 3) these
atients represent a low-risk group for in-hospital mortality.
The present study analyzes the prognostic significance of
n isolated rise in cTnT after successful nonemergency PCI
rocedures. The findings are representative of contemporary
ractice, because the majority of patients were treated with
tents (86%), atherectomy devices were used infrequently
3%), and glycoprotein IIb/IIIa inhibitors were used in
pproximately 50% of interventions. In-hospital event rates
ere extremely low regardless of cTnT status, but follow-up
eath and the combined end point of death/MI were
able 4. In-Hospital Outcomes
TnT
<0.03 ng/ml
(n  1,566)
TnT
>0.03 ng/ml
(n  383) p Value
ength of stay 0.001
1–2 days 1,391 (89%) 307 (80%)
3–4 days 120 (8%) 55 (14%)
5 days 55 (4%) 21 (5%)
eath 0 1 (0.3%) 0.20
alues expressed as n (%).
igure 1. Kaplan-Meier survival estimates for those with (TnT0.03) andC
ithout (TnT 0.03) elevated troponin. There were 40 and 80 deaths,
espectively, observed on follow-up. cTnT  cardiac troponin T.ignificantly higher in cTnT patients. Elevation in cTnT
as an independent predictor of mortality over a median
ollow-up period of 2.2 years.
omparison with previous studies. Earlier studies have
valuated the relationship between cardiac troponin I (9–14)
nd troponin T (14) with long-term mortality. However,
nlike the present investigation, all except one (11) did not
xclude patients who had elevated CK-MB after the revas-
ularization procedure. Several (10,13,14) did not exclude
atients with MI who would have had abnormal cardiac
iomarker levels at baseline. For these reasons, the reported
requency for post-procedure troponin elevation ranged
rom 17% to 48%, and although some found elevated
roponin to be an independent predictor of survival
10,12,14), others did not (9,11,13). The inconsistent find-
ngs may relate to heterogeneity in the inclusion criteria, the
ensitivity and specificity of the assay used to measure
roponin, and the duration of follow-up. The study by
atarajan et al. (11) analyzed the impact of troponin I and
xcluded patients with elevated CK-MB and pre-procedure
I. The incidence of isolated troponin elevation was similar
17%) to the present study, but troponin I was not found to
e a predictor of mortality. However, their study had a
igure 2. Kaplan-Meier estimates for survival free of death or myocardial
nfarction for those with (TnT 0.03) and without (TnT 0.03) elevated
roponin. The composite end point consisted of 19 myocardial infarctions
MI) and 35 deaths for those with elevated troponin and 68 MI and 75
eaths for those without. cTnT  cardiac troponin T.
able 5. Multiple Cox Model for Long-Term Mortality
Chi-Square
Test
Hazard Ratio
(95% CI) p Value
jection fraction 17.7 2.5 (1.6–3.8) 0.0001
alcified lesion 12.8 2.03 (1.4–3.0) 0.001
ge 11.2 1.39 (1.2–1.7) 0.001
lycoprotein IIb/IIIa use 7.7 0.58 (0.4–0.8) 0.004
aphenous vein graft PCI 7.5 1.99 (1.2–3.2) 0.006
iabetes 7.5 1.69 (1.2–2.5) 0.006
eripheral vascular disease 5.4 1.72 (1.1–2.7) 0.021
ost-PCI troponin (log2) 5.2 1.20 (1.02–1.4) 0.023
ver smoked 4.5 1.58 (1.0–2.4) 0.034I  confidence interval; PCI  percntaneous coronary intervention.
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November 7, 2006:1765–70 Troponin T and PCImaller sample size and a follow-up of only 1 year. Consis-
ent with this fact is the finding in the present investigation
hat the Kaplan-Meier curves for survival and survival free
f MI diverged after 1 year. To our knowledge, our study is
he first to report that an isolated elevation in troponin is a
redictor of outcomes.
echanisms for the adverse clinical outcomes. The re-
ationship between long-term survival and very low levels of
TnT elevation following PCI is remarkable. This suggests
hat there may be a continuous, rather than a threshold
elationship between the magnitude of rise in the biomar-
ers of myocardial injury and long-term outcomes. Two
otential mechanisms may explain this observation. First,
tudies with magnetic resonance imaging have confirmed
hat an elevation in troponin after PCI is related to
yocardial necrosis, and that there is a positive correlation
etween the magnitude of injury and the extent of troponin
elease (15). Thus, myocardial injury may impair left ven-
ricular function and predispose to arrhythmias, which
ould influence survival. Alternatively, cTnT and CK-MB
levation may be a marker for severe atherosclerosis, in-
reased plaque burden (16), presence of vulnerable plaques,
ndothelial dysfunction, microvascular injury, and inflam-
ation. Inflammation, as measured by elevated C-reactive
rotein (CRP), is an independent predictor of adverse
ong-term outcomes after PCI (1). The present study
upports the latter mechanism, because the patients with
levated cTnT were older and had more severe angina,
ultivessel disease, complex lesion morphology, coronary
hrombus, left ventricular systolic dysfunction, peripheral
ascular disease, and urgent procedures, all consistent with
dvanced or unstable coronary artery disease. Moreover,
harmacologic interventions that have antiinflammatory
nd antithrombotic effects, such as statins and glycoprotein
Ib/IIIa inhibitors have been shown to reduce the incidence
nd magnitude of myonecrosis (17,18). It seems unlikely
hat the very low level of myonecrosis observed in the
resent study would have been adequate to impact left
entricular function. One can speculate that both mecha-
isms may be at play, with minor myonecrosis serving as a
arker of advanced and active atherosclerosis and large
ncreases in biomarkers diagnosing periprocedural MI that
ould directly impact prognosis.
echanisms for the troponin elevation. Patients with
TnT elevation had greater atherosclerotic burden, as sug-
ested by a higher prevalence of multivessel disease and type
lesions and a greater number of stents used per patient.
espite these differences, procedural success and TIMI
rade 3 flow was achieved in nearly all patients. However,
TnT patients had a higher incidence of branch vessel
cclusion and coronary dissection. Abrupt closure was not
ifferent between the groups, and angiographic emboliza-
ion was not detected in any patient. These observations are
onsistent with earlier studies that have implicated branch
essel occlusion, dissection, and embolization as the mech-
nisms for the ischemic injury and myonecrosis (11,12,19).owever, angiographic complications were absent in
pproximately three-quarters of the patients with elevated
TnT. Impaired microvascular perfusion, due to plaque and
hrombus embolization, and vasoconstriction may be under-
ying mechanisms in a significant proportion of patients
20–22). This would be either undetectable by routine
ngiographic evaluation in the catheterization laboratory or
resent as slow reflow.
tudy limitations. Although the data was collected pro-
pectively, this is a retrospective single-center analysis and is
ubject to the limitations of such analyses. Furthermore,
ultiple regression models are unable to account for unob-
erved covariates that may be confounded with troponin.
ndependent core angiographic laboratory analysis to inves-
igate myocardial perfusion was not performed and may
ave provided insight into the mechanism for the cTnT
elease in patients without angiographic complications.
arkers of inflammation such as CRP were not routinely
easured. Emerging data indicate that TnT values between
he 10% CV value, which we used, and the 99th percentile
alue of 0.01 ng/ml have prognostic significance. This fact
nd the recent data concerning the potential significance of
re-PCI TnT levels for evaluating post-PCI myonecrosis
23) highlights the need for additional studies.
onclusions and clinical implications. Patients with an
solated elevation in cTnT following nonemergency PCI
epresent a very low-risk group for in-hospital major adverse
ardiac events, and their hospitalization need not be pro-
onged. However, an isolated elevation in cTnT is associ-
ted with higher rates of death and MI on follow-up,
rovides long-term prognostic information, and appears to
dentify, independent of well recognized markers of athero-
clerotic burden and ventricular function, high-risk patients
ho may benefit from more intensive secondary prevention.
urther studies using multiple biomarkers together with
maging techniques such as intravascular ultrasound and
ore angiographic laboratory analysis are required to im-
rove our understanding of the mechanisms responsible for
he myonecrosis, with the goal of improving risk stratifica-
ion and ultimately developing novel treatment strategies.
eprint requests and correspondence: Dr. Abhiram Prasad,
ayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
-mail: prasad.abhiram@mayo.edu.
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